Shares of NuVasive (NUVA) Sees Large Inflow of Net Money Flow

NuVasive (NUVA) : $9.22 million worth of transactions were on upticks in NuVasive (NUVA), compared to $5 million on downticks. The ratio between the two was 1.84, whereas, the net money flow stood at a healthy $4.22 million on Tuesdays session.The block trades show a bullish bias with only $0.75 million worth of transactions done on downticks. The consistent buying on upticks in the stock accounted for $5.13million worth of trades. The up-down ratio between the uptick and downtick was 6.8, confirming that the stronger hands have been buying the stock on every weakness. The total money flow into the stock stood at $4.37 million. The bulls and the bears were in an equilibrium as the stock closed with a loss of -0.93%. The stock was trading at $61, with a drop of $0.57 over the previous days close. The stock recorded 0.3% for the week.


The company Insiders own 4.7% of NuVasive shares according to the proxy statements. In an insider trading activity, The Securities and Exchange Commission has divulged that Hannon Jason, officer (EVP, International) of Nuvasive Inc, had unloaded 14,534 shares at an average price of $57.92 in a transaction dated on June 15, 2016. The total value of the transaction was worth $841,809.

Shares of NuVasive, Inc. rose by 1.21% in the last five trading days and 3.42% for the last 4 weeks. NuVasive, Inc. is up 22.74% in the last 3-month period. Year-to-Date the stock performance stands at 12.73%.

NuVasive (NASDAQ:NUVA): On Tuesdays trading session , Opening price of the stock was $61.57 with an intraday high of $61.81. The bears continued to sell at higher levels and eventually sold the stock down to an intraday low of $60.95. However, the stock managed to close at $61, a loss of 0.93% for the day. On the previous day, the stock had closed at $61.57. The total traded volume of the day was 491,285 shares.

Nuvasive, Inc. is a global medical device company in the spine market. The Company focuses on developing minimally-disruptive surgical products and procedurally-integrated solutions for the spine. Its marketed product portfolio is focused on applications for spine fusion surgery. Its product offering includes a minimally-disruptive surgical platform called Maximum Access Surgery (MAS). The MAS platform combines three categories of solutions that collectively minimize soft tissue disruption during spine fusion surgery, provide visualization and are designed to enable reproducible outcomes for the surgeon and the patient. The platform includes the Companys software-driven nerve detection and avoidance systems, including NVM5 and NVJJB, Intra-Operative Monitoring (IOM) services and support; MaXcess, which is an integrated split-blade retractor system, and a variety of implants and biologics.

Leave a Reply

Get Pre-Market Alerts!

Get Pre-Market Analysts' Upgrades, Downgrades, Earnings & Initiations with our FREE daily email newsletter.